Population-based input function (PBIF) applied to dynamic whole-body 68Ga-DOTATOC-PET/CT acquisition
نویسندگان
چکیده
Rational To validate a population-based input function (PBIF) model that alleviates the need for scanning since injection time in dynamic whole-body (WBdyn) PET. Methods Thirty-seven patients with suspected/known well-differentiated neuroendocrine tumors were included (GAPETNET trial NTC03576040). All WBdyn 68Ga-DOTATOC-PET/CT acquisitions performed on digital PET system (one heart-centered 6 min-step followed by nine WB-passes). The PBIF was built from 20 image-derived functions (IDIFs) obtained respective number of patients’ exams using an automated left-ventricle segmentation tool. IDIF peaks aligned to median time-to-peak, normalized patient weight and administrated activity, then fitted exponential function. applied 17 independent studies scaling it match section at 20–55 min post-injection windows corresponding WB-passes 3–7. ratio area under curves (AUCs) IDIFs 3–7 compared Bland–Altman analysis (mean bias ± SD). Patlak-estimated mean Ki physiological uptake (Ki-liver Ki-spleen) tumor lesions (Ki-tumor) either or also compared. Results AUC (PBIF/IDIF) 0.98 0.06. between −2.6 6.2% (confidence interval, CI: −5.8; 0.6). For Ki-spleen Ki-tumor, low relative SD found [4.65 7.59% (CI: 0.26; 9.03) 3.70 8.29% −1.09; 8.49) respectively]. Ki-liver analysis, slightly higher [7.43 13.13% −0.15; 15.01)]. Conclusion Our study showed approach allows reduction DOTATOC-PET/CT acquisition times minimum gain min.
منابع مشابه
Staging of neuroendocrine tumours: comparison of [68Ga]DOTATOC multiphase PET/CT and whole-body MRI
PURPOSE In patients with a neuroendocrine tumour (NET), the extent of disease strongly influences the outcome and multidisciplinary therapeutic management. Thus, systematic analysis of the diagnostic performance of the existing staging modalities is necessary. The aim of this study was to compare the diagnostic performance of 2 whole-body imaging modalities, [(68)Ga]DOTATOC positron emission to...
متن کامل[68Ga]-DOTATOC-PET/CT for meningioma IMRT treatment planning
PURPOSE The observation that human meningioma cells strongly express somatostatin receptor (SSTR 2) was the rationale to analyze retrospectively in how far DOTATOC PET/CT is helpful to improve target volume delineation for intensity modulated radiotherapy (IMRT). PATIENTS AND METHODS In 26 consecutive patients with preferentially skull base meningioma, diagnostic magnetic resonance imaging (M...
متن کاملWhole-Body 68Ga-DOTANOC PET/MRI Versus 68Ga-DOTANOC PET/CT in Patients With Neuroendocrine Tumors
PURPOSE The aim of this study was to assess the diagnostic performance of simultaneous whole-body Ga-DOTANOC PET/MRI compared with Ga-DOTANOC PET/CT for detection of distant metastatic disease in patients with well-differentiated neuroendocrine tumors (NETs). METHODS Patients with histologically proven, well-differentiated NET (G1 or G2) were included in this prospective, institutional review...
متن کاملMeningiomas: A Comparative Study of 68Ga-DOTATOC, 68Ga-DOTANOC and 68Ga-DOTATATE for Molecular Imaging in Mice
PURPOSE The goal of this study was to compare the tumor uptake kinetics and diagnostic value of three (68)Ga-DOTA-labeled somatostatin analogues ((68)Ga-DOTATOC, (68)Ga-DOTANOC, and (68)Ga-DOTATATE) using PET/CT in a murine model with subcutaneous meningioma xenografts. METHODS The experiment was performed with 16 male NUDE NU/NU mice bearing xenografts of a human meningioma cell line (CH-157...
متن کاملImpact of PET acquisition durations on image quality and lesion detectability in whole-body 68Ga-PSMA PET-MRI
BACKGROUND While 68Ga-PSMA PET-MRI might be superior to PET-CT with regard to soft tissue assessment in prostate cancer evaluation, it is also known to potentially introduce additional PET image artefacts. Therefore, the impact of PET acquisition duration and attenuation data on artefact occurrence, lesion detectability, and quantification was investigated. To this end, whole-body PET list mode...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Frontiers in nuclear medicine
سال: 2022
ISSN: ['2673-8880']
DOI: https://doi.org/10.3389/fnume.2022.941848